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l Sciences. Biomarker meashe goal of this study was to investigate the association between natriuretic peptides and body fat distribution in
a multiethnic cohort.Background Natriuretic peptides stimulate lipolysis, reduce weight gain, and promote adipocyte browning in animal models, but
data are lacking in humans.Methods A total of 2,619 participants without heart failure in the Dallas Heart Study underwent measurements of 1) B-type
natriuretic peptide (BNP) and N-terminal pro–B-type natriuretic peptide (NT-proBNP); and 2) body fat distribution by
dual energy x-ray absorptiometry andmagnetic resonance imaging. Cross-sectional associations of natriuretic peptides
with adiposity phenotypes were examined after adjustment for age, sex, race, comorbidities, and body mass index.Results Median BNP and NT-proBNP levels in the study cohort (mean age 44 years; 56% women, 48% African Americans,
32% obese) were 3.0 and 28.1 pg/ml, respectively. Natriuretic peptide levels above the median were associated
with a more favorable body fat proﬁle and less insulin resistance, including lower visceral fat, liver fat, and
homeostasis model assessment of insulin resistance index, and increased lower body fat and higher adiponectin
(p < 0.05 for each). In multivariable analyses, NT-proBNP remained inversely associated with visceral fat (beta
coefﬁcient¼ 0.08; p < 0.0001) and liver fat (beta coefﬁcient¼ 0.14; p< 0.0001) and positively associated with
lower body fat (beta coefﬁcient ¼ 0.07; p < 0.0001) independent of age, sex, race, and obesity status; ﬁndings were
similar with BNP. Adjustment for body composition, homeostasis model assessment of insulin resistance index,
circulating androgens, and adipocytokines did not attenuate the associations.Conclusions Higher natriuretic peptide levels were independently associated with a favorable adiposity proﬁle, characterized by
decreased visceral and liver fat and increased lower body fat, suggesting a link between the heart and adipose
tissue distribution mediated through natriuretic peptides. (J Am Coll Cardiol 2013;62:752–60) ª 2013 by the
American College of Cardiology FoundationSee page 761An inverse relationship between natriuretic peptide levels and
obesity, traditionally deﬁned by body mass index (BMI), has
been ﬁrmly established (1–3). However, controversy exists asedicine, Division of Cardiology, University of
allas, Texas; yDepartment of Clinical Sciences,
edical Center, Dallas, Texas; zDepartment of
ocrinology, Metabolism and Diabetes, Mayo
e xCenter for Human Nutrition, University of
Dallas, Texas. This work was supported by award
tional Heart, Lung, and Blood Institute to Dr.
d PL1DK081182 from the National Institutes of
000451 from the National Center for Advancing
urements were supported by investigator-initiated
grants from Roche Diagnostics and Alere Inc. Dr. McGuire has received research support
from Orexigen as member of the Data Safety Monitoring Committee for an obesity trial;
and has served as a consultant and/or received research support for the following: sanoﬁ-
aventis, Boehringer Ingelheim, Takeda Pharmaceuticals, Janssen Pharmaceuticals, Gen-
entech, Roche Diagnostics, Pﬁzer, AstraZeneca, Bristol-Myers Squibb, Daiichi Sankyo,
Merck, Orexigen, Regeneron, and Eli Lilly & Company. Dr. de Lemos has received
research support from Roche Diagnostics and Abbott Diagnostics. All other authors have
reported that they have no relationships relevant to the contents of this paper to disclose.
Manuscript received January 8, 2013; revised manuscript received February 21,
2013, accepted March 12, 2013.
Abbreviations
and Acronyms
BMI = body mass index
BNP = B-type natriuretic
peptide
BSA = body surface area
CVD = cardiovascular
disease
GFR = glomerular ﬁltration
rate
HOMA-IR = homeostasis
model assessment of insulin
resistance index
LV = left ventricular
LVH = left ventricular
hypertrophy
MRI = magnetic resonance
imaging
NPR = natriuretic peptide
receptors
NT-proBNP = N-terminal
pro–B-typenatriuretic peptide
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753to the nature of this relationship and whether obesity inﬂu-
ences, or is primarily inﬂuenced by, circulating natriuretic
peptide levels. Although it was originally hypothesized that
lower natriuretic peptide levels in obese individuals could be
attributed to increased clearance by adipose tissue expressing
the natriuretic peptide receptors (NPR)-C, studies have
demonstrated that natriuretic peptides not cleared via this
mechanism, such as N-terminal pro–B-type natriuretic
peptide (NT-proBNP) and N-terminal atrial natriuretic
peptide, have similar inverse associations with BMI. This
suggests that decreased natriuretic peptide release from the
heart, rather than clearance by adipose tissue, underlies this
relationship (4,5).
A growing body of experimental evidence suggests that the
heart exerts beneﬁcial metabolic effects on adipose tissue
metabolism and function through release of natriuretic
peptides. Atrial natriuretic and B-type natriuretic peptides
(BNPs) bind to NPR-A receptors on adipose tissue and
stimulate lipolysis (6), promote browning of adipocytes (7),
regulate body fat distribution by activation of peroxisome
proliferator-activated receptor gamma gene expression (8),
and enhance adiponectin secretion from adipocytes (9). As
a result, mice that overexpress or are treated with exogenous
infusions of natriuretic peptide exhibit reduced fat mass,
improved glucose tolerance, and enhanced energy expendi-
ture (7), suggesting that the “lipomobilizing” effects of
natriuretic peptides may have salutary consequences on
body fat metabolism and distribution. Conversely, a relative
natriuretic peptide deﬁciency may contribute to obesity and
an adverse adipose tissue distribution proﬁle (10). However,
data are lacking on the relationship of natriuretic peptides
with adiposity phenotypes in humans.
We therefore investigated the cross-sectional associations
of natriuretic peptide levels with body fat composition by
using dual-energy x-ray absorptiometry and abdominal fat
distribution by magnetic resonance imaging (MRI) in a large,
multiethnic cohort of adults with extensive cardiovascular,
metabolic, and adipose tissue imaging phenotyping. We
hypothesized that higher levels of natriuretic peptides would
be associated with a favorable adiposity proﬁle, characterized
by decreased visceral and liver fat and increased lower body
(gluteal-femoral) subcutaneous fat independent of age, sex,
race, and obesity status. In addition, we tested whether
accounting for endocrine factors known to be associated with
natriuretic peptides and adipose tissue distribution, including
levels of insulin resistance, circulating androgens, and adi-
pocytokines, would affect this relationship.Methods
Study population. The DHS (Dallas Heart Study) is a
multiethnic, probability-based, population cohort study of
Dallas County adults, with a deliberate oversampling
of African-American subjects. Detailed methods of the
DHS have been described previously (11). Brieﬂy, between
2000 and 2002, a total of 3,072 subjects completed the3 DHS visits, including a de-
tailed in-home survey, laboratory
testing, and imaging studies. For
the current study, participants
with a left ventricular (LV) ejec-
tion fraction <50%, those with
prevalent clinical heart failure
(deﬁned by self-report of “con-
gestive heart failure, an enlarged
heart, a weak heart, or cardiomy-
opathy”), and those with missing
natriuretic peptide data were
excluded, yielding a ﬁnal sample
size of 2,619. Participants pro-
vided written informed consent,
and the protocol was approved by
the institutional review board of
the University of Texas South-
western Medical Center.
Race/ethnicity, history of car-
diovascular diseases (CVD), and
smoking status were self-reported.
Detailed descriptions of variable
deﬁnitions for hypertension, hypercholesterolemia, and low
high-density lipoprotein cholesterol have been previously
described using conventional clinical deﬁnitions (12). Presence
of the metabolic syndrome was deﬁned according to the
National Cholesterol Education Program’s Adult Treatment
Panel III report (13). Glomerular ﬁltration rate (GFR) was
estimated by using the Modiﬁcation of Diet in Renal Disease
equation (14). The homeostasis model assessment of insulin
resistance index (HOMA-IR) was calculated according
to fasting insulin (mIU/ml)  fasting glucose (mmol/l)/22.5
(15).
Natriuretic peptide, androgen, and adipocytokine mea-
surements. Detailed methods describing measurements of
NT-proBNP (Roche Diagnostics, Indianapolis, Indiana)
and BNP (Alere Inc., San Diego, California) in the DHS
have been published previously (4). The coefﬁcient of vari-
ation for the NT-proBNP assay was 3.3% at a concentration
of 282 pg/ml and 3.0% at a concentration of 6,012 pg/ml;
for the BNP assay, it was 11.2% at a concentration of
30 pg/ml and 5.8% at concentrations >60 pg/ml. Total
testosterone was measured in a subgroup of 695 women
by using a competitive radioimmunoassay as previously
described (16). The assay had a coefﬁcient of variation of
7.7% at a concentration of 0.52 ng/ml. Circulating free
testosterone was then calculated by using a published esti-
mating equation previously validated in women (17). Adi-
pocytokines including total adiponectin (18), leptin, and
highly sensitive C-reactive protein levels were measured as
previously described (19).
Body fat distribution and imaging measurements. BMI
was calculated as weight (kilograms)/height (meters)2.
Body surface area (BSA) was calculated according to the
method of Tikuisis et al. (20). Waist circumference was
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754measured 1 cm above the iliac crest, and hip circumference
was measured at the widest circumference of the buttocks
at the area of the greater trochanters. Dual-energy x-ray
absorptiometry (Delphi W scanner, Hologic Inc., Bedford,
Massachusetts, and Discovery software [version 12.2],
Discovery Software Ltd., Bellingham, Washington) was
used to measure total body fat, lean mass, percent body fat,
and lower body subcutaneous fat. Lower body fat was
delineated by 2 oblique lines crossing the femoral necks and
converging below the pubic symphysis, and included gluteal-
femoral fat (21). Visceral and subcutaneous abdominal fat
mass were measured by using a 1.5-T MRI system (Intera,
Philips Medical Systems, Best, the Netherlands) using a
prospectively designed and validated method of fat mass
prediction from a single MRI slice at the L2-L3 interver-
tebral level (22). Single-slice measurement of subcutaneous
and visceral fat mass at this intervertebral level has been
shown to be highly concordant with total abdominal fat
mass measured at all intervertebral levels (R2 ¼ 85% to 96%)
(22). Liver fat was measured by using a 1.5-T 1H magnetic
resonance spectroscopy and is reported as a percentage (23).
Cardiac MRI was performed by using the same afore-
mentioned 1.5-T system. Left ventricular (LV) mass, end-
diastolic and end-systolic volumes, and ejection fraction
were calculated from short-axis sequences. Left ventricular
hypertrophy (LVH) was deﬁned as LV mass/BSA 89 g/m2
in women and 112 g/m2 in men, based on a phenotypically
normal subpopulation of the DHS cohort (24).
Statistical analysis. Characteristics were compared between
participants with natriuretic peptide levels above and below
median values by using chi-square tests for dichotomous
variables and Wilcoxon rank sum tests for continuous
variables. Linear regression modeling was used to assess
associations of natriuretic peptides with adiposity pheno-
types, with the log-transformed natriuretic peptide as the
independent variable and the adiposity measurement as the
dependent variable. Standardized beta coefﬁcients were
used to facilitate comparisons between natriuretic peptides
and adiposity measurements. The beta coefﬁcient represents
the unit change in 1 SD of the adiposity variable for a 1 SD
change in the log-transformed natriuretic peptide level.
Models were adjusted for age, sex, African-American race,
hypertension, diabetes, LV mass/BSA, estimated GFR,
smoking, and BMI. As a sensitivity analysis, multivariable
models were created replacing BMI with total body fat and
lean mass to assess the associations of natriuretic peptides
with body fat distribution independent of overall fat and
lean mass. Due to potential collinearity by inclusion of both
fat and lean mass in multivariable models, variance inﬂation
factors were tested, which were consistently <5. Multi-
variable models were also tested with additional adjustment
for LV end-diastolic volume/BSA, menopausal status in
women, and adipocytokine levels, as well as by replacement
of hypertension and diabetes status with systolic blood
pressure and HOMA-IR. Sensitivity analyses were per-
formed excluding participants with hypertension, diabetes,GFR <60 ml/min/1.73 m2, LVH, and CVD. Lastly, the
impact of circulating androgens on the relationship between
natriuretic peptides and body composition was explored in
a subgroup of 695 women age 50 years with concurrent
plasma free testosterone measurements.
For all statistical testing, a 2-sided p value <0.05 was
considered statistically signiﬁcant. All statistical analyses
were performed by using SAS version 9.2 (SAS Institute,
Inc., Cary, North Carolina).Results
Univariable associations of natriuretic peptides with body
fat composition. Among the 2,619 participants meeting
study criteria, the mean age was 44; 56% were women and
48% were African American. Twenty-four percent of the
study cohort was normal weight (BMI <25 kg/m2), 44%
overweight (25  BMI < 30 kg/m2), and 32% obese
(BMI 30 kg/m2). The median (25th, 75th percentile) NT-
proBNP and BNP levels in the study cohort were 28.1
(13.2, 58.9) and 3.0 (0.0, 13.0) pg/ml, respectively. Baseline
characteristics are presented in Table 1. Compared with
individuals with natriuretic peptide levels below the median
value, those with levels above the median were older and
more likely to be female with greater prevalence of hyper-
tension, LVH, and CVD (p < 0.05 for each).
Natriuretic peptide levels above the median value were
associated with a more favorable body fat composition proﬁle
and less insulin resistance, including signiﬁcantly lower
weight, waist circumference, waist–hip ratio, and HOMA-
IR, and higher adiponectin levels (p < 0.05 for each)
(Table 1). Although participants with higher natriuretic
peptide levels had less lean mass and more total body fat, the
relationship between natriuretic peptides and total body fat
was determined primarily through a positive association with
lower body fat (i.e., gluteal-femoral) despite an inverse asso-
ciation with visceral and liver fat (p < 0.05 for each). The
inverse association of natriuretic peptide levels with visceral fat
and the positive association with lower body fat were generally
consistent across BMI strata of normal weight, overweight,
and obese for both NT-proBNP and BNP (Fig. 1).
Multivariable adjustment. After multivariable adjustment
for age, sex, African-American race, hypertension, diabetes,
LV mass/BSA, estimated GFR, smoking, and BMI, natri-
uretic peptide levels remained inversely associated with
visceral fat (beta coefﬁcient ¼ 0.08 for NT-proBNP
and 0.04 for BNP; p  0.01 for both) and liver fat (beta
coefﬁcient ¼ 0.14 for NT-proBNP and 0.06 for BNP;
p  0.01 for both) (Table 2). The inverse associations of
natriuretic peptides with liver fat remained signiﬁcant
after additional adjustment for visceral fat mass (beta
coefﬁcient ¼ 0.10 for NT-proBNP, p < 0.0001 and
0.05 for BNP, p ¼ 0.01). In contrast, both NT-proBNP
(beta coefﬁcient ¼ 0.07) and BNP (beta coefﬁcient ¼ 0.04)
were positively associated with lower body fat (p < 0.0001 for
both). Results were unchanged after replacement of BMI with
Table 1 Characteristics of the Study Population Stratiﬁed by Natriuretic Peptide Levels
Variable
NT-proBNP BNP
 Median
(n ¼ 1,310)
> Median
(n ¼ 1,309)
 Median
(n ¼ 1,392)
> Median
(n ¼ 1,227)
Age (yrs) 41 (34, 48) 46 (38, 54)* 41 (35, 49) 45 (37, 53)y
Male (%) 58.7 30.2* 51.1 37.8y
Race (%)
White 28.2 36.2* 31.5 33.0
African-American 52.1 44.1* 48.1 48.0
Hispanic 16.8 18.4 18.2 17.0
Hypertension (%) 27.2 36.6* 27.9 35.9y
Diabetes (%) 10.5 10.5 10.7 10.3
Hypercholesterolemia (%) 12.7 12.5 11.6 13.5
Low HDL cholesterol (%) 41.7 38.4 38.7 41.4
Metabolic syndrome (%) 34.2 33.2 33.2 34.2
Current smoking (%) 28.1 26.9 28.0 26.9
Previous CVD (%) 2.2 5.7* 2.7 5.2y
Left ventricular hypertrophy (%) 7.4 11.9* 7.4 11.9y
Weight (kg) 85.0 (73.0, 99.3) 78.5 (66.7, 93.0)* 83.2 (71.4, 98.0) 80.7 (68.5, 95.3)y
Body mass index (kg/m2) 29.5 (25.8, 33.9) 28.5 (24.5, 33.8)* 29.3 (25.3, 34.0) 28.9 (25.1, 33.8)
Waist circumference (cm) 99.0 (90.0, 110.0) 95.0 (84.0, 106.0)* 97.5 (88.0, 109.5) 96.0 (86.0, 107.5)y
Waist/hip ratio 0.92 (0.87, 0.98) 0.88 (0.82, 0.94)* 0.91 (0.85, 0.97) 0.89 (0.83, 0.95)y
Total fat mass (kg) 24.7 (17.9, 32.2) 26.1 (19.1, 34.7)* 24.7 (17.7, 32.5) 26.1 (19.2, 34.5)y
Total lean mass (kg) 58.7 (49.5, 66.6) 50.0 (43.0, 58.9)* 56.3 (47.1, 65.3) 52.4 (44.4, 61.6)y
Visceral fat (kg) 2.2 (1.6, 2.9) 1.9 (1.3, 2.6)* 2.1 (1.5, 2.8) 1.9 (1.4, 2.6)y
Abdominal subcutaneous fat (kg) 4.1 (2.8, 6.1) 4.4 (2.8, 6.4) 4.0 (2.8, 6.1) 4.4 (2.8, 6.4)y
Lower body fat (kg) 8.1 (5.8, 11.3) 9.4 (6.7, 12.6)* 8.3 (5.8, 11.8) 9.3 (6.5, 12.4)y
Liver fat (%) 3.9 (2.3, 7.8) 3.2 (1.9, 5.6)* 3.7 (2.2, 7.1) 3.4 (2.0, 5.9)y
LV ejection fraction (%) 72.7 (68.0, 77.1) 73.6 (68.5, 77.9)* 73.0 (68.2, 77.3) 73.3 (68.3, 77.6)
LV end-diastolic volume/BSA (ml/m2) 51.0 (45.2, 57.5) 50.8 (44.5, 58.4) 51.0 (45.1, 57.5) 51.1 (44.6, 58.4)
LV end-systolic volume/BSA (ml/m2) 14.0 (11.0, 17.2) 13.3 (10.6, 16.7)* 13.8 (11.0, 16.8) 13.7 (10.6, 17.2)
Estimated GFR (ml/min/1.73 m2) 98.8 (87.1, 112.6) 95.3 (82.4, 111.2)* 98.0 (85.4, 112.6) 96.6 (84.1, 111.4)
HOMA-IR 3.2 (1.8, 5.3) 2.5 (1.4, 4.4)* 3.0 (1.7, 5.2) 2.6 (1.6, 4.6)y
Adiponectin (ng/ml) 5.6 (4.0, 8.2) 8.0 (5.2, 11.3)* 5.9 (4.1, 8.8) 7.5 (4.9, 10.7)*
BNP (pg/ml) 0.0 (0.0, 3.8) 9.2 (2.4, 22.4) 0.0 (0.0, 0.5) 13.0 (6.7, 24.2)
NT-proBNP (pg/ml) 13.2 (5.8, 19.5) 58.9 (39.8, 99.4) 16.8 (7.5, 30.3) 50.6 (25.8, 94.3)
Values are median (25%, 75% percentile) or proportion (%). Median values for N-terminal pro–B-type natriuretic peptide (NT-proBNP) and B-type natriuretic peptide (BNP) are 28.1 and 3.0 pg/ml, respectively.
*p < 0.05 versus  median NT-proBNP group. yp < 0.05 versus  median BNP group.
BP ¼ blood pressure; BSA ¼ body surface area; CVD ¼ cardiovascular disease; GFR ¼ glomerular ﬁltration rate; HDL ¼ high-density lipoprotein; HOMA-IR ¼ homeostasis model assessment of insulin
resistance; LV¼ left ventricular.
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755total body fat and leanmass in themodels. Although bothNT-
proBNP and BNP were associated with increased abdominal
subcutaneous fat after multivariable adjustment in the model
containing BMI (beta coefﬁcient¼ 0.04 for NT-proBNP and
0.03 for BNP; p  0.01 for both), results were completely
attenuated after adjustment for total fat and lean mass
(Table 2). All ﬁndings were insensitive to exclusion of partic-
ipants with hypertension, diabetes, GFR <60 ml/min/1.73
m2, LVH, andCVD; the ﬁndings were similar after additional
adjustment for LV end-diastolic volume/BSA, menopausal
status (in women), treatment with antihypertensive and statin
medications, and adipocytokine levels in the models, and by
replacement of hypertension and diabetes status with systolic
blood pressure and HOMA-IR (Online Table 1). Findings
were also similar when using sex-speciﬁc and age-stratiﬁed
multivariable adjusted models (Online Tables 2 and 3). The
multivariable adjusted association between higher natriuretic
peptide levels and lower visceral fat was consistent acrosssubgroups deﬁned according to age, sex, race, and obesity
status, with no interactions observed (Fig. 2). Exploratory
analyses examining the relation between natriuretic peptides
and the more clinically relevant anthropometric measure of
waist–hip ratio demonstrated an inverse association after
multivariable adjustment (beta coefﬁcient ¼ 0.08 for
NT-proBNP [p < 0.0001] and 0.04 for BNP [p ¼ 0.03]).
Effect of testosterone on the relationship between
natriuretic peptides and adiposity phenotypes. In ex-
ploratory analyses restricted to 695 women age 50 years
with concurrent plasma free testosterone measurements, the
impact of circulating androgens on the association between
natriuretic peptides and body fat composition was examined.
The median (25th, 75th percentile) free testosterone level
in this subgroup was 1.7 (1.3, 2.2) ng/ml, and the correlation
coefﬁcients (Spearman’s rho) between free testosterone
and natriuretic peptides were 0.13 (p ¼ 0.001) and 0.08
(p ¼ 0.04) for NT-proBNP and BNP, respectively. In
Figure 1 Fat Mass Stratiﬁed by Obesity Category and Natriuretic Peptide Concentrations
Mean  SEM visceral fat mass stratiﬁed according to median N-terminal pro–B-type natriuretic peptide (NT-proBNP) is shown in A and by median BNP in B. Mean  SEM lower
body fat mass stratiﬁed by NT-proBNP is shown in C and by BNP in D. Body mass index (BMI) is categorized as follows: normal weight, BMI <25 kg/m2 (n ¼ 614); overweight,
25  BMI < 30 kg/m2 (n ¼ 844); obese BMI 30 kg/m2 (n ¼ 1,130). *p < 0.05 vs.  median group.
Neeland et al. JACC Vol. 62, No. 8, 2013
Natriuretic Peptides and Fat Distribution August 20, 2013:752–60
756multivariable analyses among this subgroup adjusting for
age, African-American race, hypertension, diabetes, LV
mass/BSA, estimated GFR, smoking, BMI, and the log-
transformed natriuretic peptide level, free testosterone was
independently associated with increased visceral fat (beta
coefﬁcient ¼ 0.13, p < 0.0001) and negatively associated
with lower body fat (beta coefﬁcient ¼ 0.05; p< 0.05), but
showed no statistically signiﬁcant association with abdom-
inal subcutaneous or liver fat. Importantly, additional
adjustment for free testosterone in the multivariable modelsTable 2 Multivariable-Adjusted Linear Regression Models of Relation
Variable
Visceral Fat Abdominal Subcutane
Beta Coefﬁcient p Value Beta Coefﬁcient
Log NT-proBNP
Model 1 (unadjusted) 0.16 <0.0001 0.05
Model 2 0.08 <0.0001 0.04
Model 3 0.10 <0.0001 0.0004
Log BNP
Model 1 (unadjusted) 0.09 <0.0001 0.03
Model 2 0.04 0.006 0.03
Model 3 0.06 <0.0001 0.003
Models constructed with fat parameter as dependent variable and natriuretic peptide as independent
unadjusted. Model 2 was adjusted for age, sex, African-American race, hypertension, diabetes, left ventri
Model 3 was adjusted for all covariates from model 2 replacing body mass index with total body fat madid not attenuate the associations observed between natri-
uretic peptides and adiposity phenotypes (Online Table 4),
suggesting that the relationship between natriuretic peptides
and body composition may be independent of circulating
androgen levels.Discussion
In this large, population-based cohort of community-dwelling
adults with well-characterized body fat composition andof Natriuretic Peptides to Adiposity Phenotypes
ous Fat Lower Body Fat Liver Fat
p Value Beta Coefﬁcient p Value Beta Coefﬁcient p Value
0.01 0.13 <0.0001 0.13 <0.0001
0.0001 0.07 <0.0001 0.14 <0.0001
0.95 0.04 <0.0001 0.15 <0.0001
0.11 0.08 <0.0001 0.08 0.0001
0.0004 0.04 <0.0001 0.06 0.002
0.66 0.02 0.007 0.08 0.0004
variable; the beta coefﬁcient is per 1 SD of the log-transformed natriuretic peptide. Model 1 was
cular mass/body surface area, estimated glomerular ﬁltration rate, smoking, and body mass index.
ss and lean mass.
Figure 2 Multivariable Adjusted Associations
Multivariable adjusted associations of natriuretic peptides with the lowest sex-speciﬁc quartile of visceral fat mass (<1.3 kg for women and <1.8 kg for men) by age, sex,
race, and obesity subgroups. Odds ratios (OR) (95% conﬁdence intervals [CI]) per 1 SD increment in the log-transformed natriuretic peptide level. Adjusted for age, sex,
African-American race, hypertension, diabetes, left ventricular mass/body mass index, estimated glomerular ﬁltration rate, smoking, and total body fat and lean mass.
p value for subgroup interaction. Abbreviations as in Figure 1.
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757distribution, we demonstrated a signiﬁcant association
between higher levels of natriuretic peptides and a favorable
adiposity proﬁle, including decreased visceral and liver fat and
increased lower body fat, independent of age, sex, race, and
obesity status. Accounting for levels of insulin resistance,
circulating androgens, and adipocytokines did not attenuate
this association, suggesting that the link between natriuretic
peptides and body fat distribution may be at least partially
independent of peripheral endocrine effects. In addition,
although visceral, liver, and lower body fat are highly sex
dependent, with less visceral and liver fat and greater lower
body fat seen among females, our ﬁndings do not suggest that
the relationship between higher natriuretic peptide levels and
a “gynoid” adiposity proﬁle is mediated exclusively through
female sex; as the ﬁndings were independent of sex in the
models and were consistent in subgroups of men and women.
Taken in the context of previous experimental and epidemi-
ological evidence, our observations provide insight into the
potential interplay between the heart and adipose tissue,
generating the hypothesis that natriuretic peptides released by
cardiomyocytes may exert beneﬁcial effects on fat metabolism
in humans.
Few studies have examined the relationship between
natriuretic peptides and precise estimates of body fatdistribution. A study of 608 patients with type 2 diabetes
from Japan demonstrated an inverse association between
BNP and BMI, with a more robust inverse association
between BNP and visceral fat compared with other measures
of adiposity (25). A more recent report among third-
generation participants in the Framingham Heart Study
similarly described inverse associations between NT-
proBNP and visceral fat in a multivariable adjusted analysis
including BMI, with no independent association seen with
abdominal subcutaneous fat (26). In addition to conﬁrming
the link between natriuretic peptides and reduced visceral fat
among a larger and more ethnically diverse population, with
greater insulin resistance and more extensive cardiac phe-
notyping, we demonstrated several novel ﬁndings. These
include an inverse association with liver fat, a well-known
correlate of diabetes and the metabolic syndrome (27), and
a positive association with lower body fat, an adipose tissue
depot gaining increasing recognition as potentially protective
against many CVD risk factors. Although the associations
observed in our study were relatively small in magnitude,
they are consistent with those seen in the Framingham Heart
Study (26) and may relate to the use of log-transformed
natriuretic peptide levels in both analyses. In addition, the
distribution of natriuretic peptide levels in our population
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increases within this range are expected to have smaller
effect sizes.
The positive association with lower body fat is particularly
notable, as preferential storage of excess adiposity in the
lower body subcutaneous fat compartment is associated with
a lower prevalence of metabolic risk factors (21,28), and loss
of this fat reservoir over time may result in higher blood
pressure, cholesterol, and blood glucose levels (29). In the
prospective Malmo Diet and Cancer study (30), higher
natriuretic peptide levels were associated with a lower inci-
dence of diabetes over follow-up, and we have recently
reported in the DHS that greater lower body fat may protect
against diabetes development (31). The current ﬁndings
suggest a link between these last 2 observations and raise the
possibility that fat redistribution to the lower body subcu-
taneous compartment may represent a mechanism by which
natriuretic peptides protect against insulin resistance and
diabetes. In addition, because our ﬁndings demonstrate that
natriuretic peptide levels have variable relationships with
different adipose tissue depots, analyses limited to total body
measurements of adiposity may not accurately characterize
the complex relationship between natriuretic peptides and
body fat.
Potential mechanisms. Natriuretic peptide signaling may
actively inﬂuence differential body fat distribution. Although
natriuretic peptides have lipolytic and lipomobilizing effects
on adipose tissue (32), the magnitude of lipolysis may vary
among different adipose tissue depots. For example, the rate
of lipolysis is lowest in subcutaneous gluteal-femoral fat,
intermediate in abdominal subcutaneous fat, and highest in
visceral fat (33). Natriuretic peptides may differentially
inﬂuence lipolysis through higher NPR-A receptor expres-
sion within visceral fat compared with subcutaneous fat (34),
making lower body subcutaneous fat relatively resistant to
natriuretic peptide–mediated lipolysis.
An alternative explanation for our ﬁndings could be that
the association between natriuretic peptides and adiposity
may indeed be bidirectional. Experimental and observa-
tional data suggest that increased body mass leads to
decreased natriuretic peptide levels (1–4) and, conversely,
that weight loss increases natriuretic peptide levels (35,36).
The development of abdominal obesity may result in
a vicious cycle, with inhibition of natriuretic peptide–
mediated lipolysis and perpetuation of visceral and liver fat
accumulation, ultimately resulting in an adverse adiposity
proﬁle and metabolic disease. Obese individuals without
heart failure may also be prone to a relative natriuretic
peptide deﬁciency stemming from suppressive effects of
circulating androgens on natriuretic peptide synthesis (16)
and possibly from the systemic lipotoxic and cytokine
effects of ectopic fat on cardiac tissue (37), leading to
impaired natriuretic peptide synthesis (38) and release (39).
This vicious cycle may be augmented by further suppression
of natriuretic peptide levels through increased clearance via
the NPR-C receptor expressed in adipose tissue, with morerigorous clearance among those with central abdominal
obesity. In support of this theory are the ﬁndings that NPR-
C gene expression is up-regulated in visceral fat compared
with subcutaneous fat in both insulin-sensitive and insulin-
resistant individuals (34).
Strengths and limitations. Strengths of the current study
include a racially diverse sample of adults applicable to the
general population and detailed phenotyping according to
multiple novel adipose tissue-imaging techniques. Several
limitations also merit comment. Because the analysis was
cross-sectional, we were unable to determine the direction-
ality of the relationship between natriuretic peptides and
body fat distribution beyond what has been suggested from
experimental data; therefore, the ﬁndings of this study
should be viewed as hypothesis generating and require
further conﬁrmation in prospective studies with serial
assessment of body fat distribution. Second, although we
excluded participants with self-reported prevalent heart
failure and LV systolic dysfunction, the contribution of
undiagnosed heart failure with preserved ejection fraction to
natriuretic peptide levels cannot be quantiﬁed; however,
individuals with this disorder tend to be overweight or obese,
thereby increasing type II error and biasing our study toward
the null hypothesis instead of increasing the likelihood of
false-positive results. Third, because total abdominal
subcutaneous adipose tissue was measured in our study, we
were unable to test the independent associations of its
superﬁcial and deep components (which may have divergent
relationships with cardiometabolic risk markers) with
natriuretic peptides. Fourth, we are unable to examine the
role that adipocytokines other than adiponectin, leptin, and
C-reactive protein may play in the relationship between
natriuretic peptides and body fat distribution. Lastly, the
current ﬁndings are not necessarily generalizable to indi-
viduals age >65 years, of Asian descent/ethnicity, or with
symptomatic heart failure in whom both body fat distribu-
tion and natriuretic peptide levels may be different compared
with our study population.
Conclusions
It has become increasingly evident that the impact of obesity
on cardiovascular and metabolic risk is heterogeneous and
highly dependent on the distribution and consequent
metabolic activity of body fat. For example, the accumula-
tion of fat around the abdominal viscera and other ectopic
sites such as the heart and liver is associated with multiple
CVD risk factors (40) and the development of diabetes (31).
In contrast, increased fat storage in the lower body gluteal-
femoral region seems to ameliorate some of the risk asso-
ciated with adiposity (21,41). Therefore, the discovery that
natriuretic peptides can favorably affect body fat metabolism
and distribution in animal experiments, and its translation
into human epidemiology, has several implications. First, the
ﬁnding that natriuretic peptides differentially associate with
body fat composition measures, irrespective of obesity status,
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adipose tissue depots and their relation with the cardiovas-
cular system. Second, up-regulating the natriuretic peptide
system among obese individuals represents a potential
therapeutic approach to treating abdominal obesity and its
adverse metabolic and vascular effects. For example,
although its use was abandoned due to excess risk of
angioedema, the vasopeptidase inhibitor omapatrilat raised
natriuretic peptide levels, leading to improved sodium/water
balance and decreased peripheral vascular resistance and
blood pressure (42). Another strategy may be to increase
physical activity, because exercise both enhances natriuretic
peptide release (43) and preferentially reduces visceral fat
mass independent of weight loss (44). If our ﬁndings are
prospectively conﬁrmed, similar therapeutic strategies aimed
at increasing natriuretic peptide levels may be targeted to
reduce accumulation of visceral and ectopic fat and drive
redistribution to more metabolically favorable adipose
storage depots.
Reprint requests and correspondence: Dr. Ian J. Neeland,
University of Texas Southwestern Medical Center, 5323 Harry
Hines Boulevard, Mail Code 8830, Dallas, Texas 75390. E-mail:
ian.neeland@utsouthwestern.edu.REFERENCES
1. Wang TJ, Larson MG, Levy D, et al. Impact of obesity on plasma
natriuretic peptide levels. Circulation 2004;109:594–600.
2. Mehra MR, Uber PA, Park MH, et al. Obesity and suppressed B-type
natriuretic peptide levels in heart failure. J Am Coll Cardiol 2004;43:
1590–5.
3. McCord J, Mundy BJ, Hudson MP, et al. Relationship between
obesity and B-type natriuretic peptide levels. Arch Intern Med 2004;
164:2247–52.
4. Das SR, Drazner MH, Dries DL, et al. Impact of body mass and body
composition on circulating levels of natriuretic peptides: results from
the Dallas Heart Study. Circulation 2005;112:2163–8.
5. Costello-Boerrigter LC, Burnett JC Jr. A new role for the natriuretic
peptides: metabolic regulators of the adipocyte. J Am Coll Cardiol
2009;53:2078–9.
6. Sengenes C, Berlan M, De Glisezinski I, Lafontan M, Galitzky J.
Natriuretic peptides: a new lipolytic pathway in human adipocytes.
FASEB J 2000;14:1345–51.
7. Bordicchia M, Liu D, Amri EZ, et al. Cardiac natriuretic peptides act
via p38 MAPK to induce the brown fat thermogenic program in mouse
and human adipocytes. J Clin Invest 2012;122:1022–36.
8. Miyashita K, Itoh H, Tsujimoto H, et al. Natriuretic peptides/cGMP/
cGMP-dependent protein kinase cascades promote muscle mitochon-
drial biogenesis and prevent obesity. Diabetes 2009;58:2880–92.
9. Tsukamoto O, Fujita M, Kato M, et al. Natriuretic peptides enhance
the production of adiponectin in human adipocytes and in patients with
chronic heart failure. J Am Coll Cardiol 2009;53:2070–7.
10. Clerico A, Giannoni A, Vittorini S, Passino C. Thirty years of the
heart as an endocrine organ: physiological role and clinical utility of
cardiac natriuretic hormones. Am J Physiol Heart Circ Physiol 2011;
301:H12–20.
11. Victor RG, Haley RW, Willett DL, et al. The Dallas Heart Study:
a population-based probability sample for the multidisciplinary study of
ethnic differences in cardiovascular health. Am J Cardiol 2004;93:
1473–80.
12. Deo R, Khera A, McGuire DK, et al. Association among plasma levels
of monocyte chemoattractant protein-1, traditional cardiovascular riskfactors, and subclinical atherosclerosis. J Am Coll Cardiol 2004;44:
1812–8.
13. Third Report of the National Cholesterol Education Program (NCEP)
Expert Panel on Detection, Evaluation, and Treatment of High Blood
Cholesterol in Adults (Adult Treatment Panel III) ﬁnal report.
Circulation 2002;106:3143–421.
14. Levey AS, Adler S, Caggiula AW, et al. Effects of dietary protein
restriction on the progression of advanced renal disease in the Modi-
ﬁcation of Diet in Renal Disease Study. Am J Kidney Dis 1996;27:
652–63.
15. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF,
Turner RC. Homeostasis model assessment: insulin resistance and
beta-cell function from fasting plasma glucose and insulin concentra-
tions in man. Diabetologia 1985;28:412–9.
16. Chang AY, Abdullah SM, Jain T, et al. Associations among
androgens, estrogens, and natriuretic peptides in young women:
observations from the Dallas Heart Study. J Am Coll Cardiol 2007;49:
109–16.
17. Vermeulen A, Verdonck L, Kaufman JM. A critical evaluation of
simple methods for the estimation of free testosterone in serum. J Clin
Endocrinol Metab 1999;84:3666–72.
18. Turer AT, Khera A, Ayers CR, et al. Adipose tissue mass and
location affect circulating adiponectin levels. Diabetologia 2011;54:
2515–24.
19. Abdullah SM, Khera A, Leonard D, et al. Sex differences in the
association between leptin and CRP: results from the Dallas Heart
Study. Atherosclerosis 2007;195:404–10.
20. Tikuisis P, Meunier P, Jubenville CE. Human body surface area:
measurement and prediction using three dimensional body scans. Eur J
Appl Physiol 2001;85:264–71.
21. Vega GL, Adams-Huet B, Peshock R,Willett D, Shah B, Grundy SM.
Inﬂuence of body fat content and distribution on variation in metabolic
risk. J Clin Endocrinol Metab 2006;91:4459–66.
22. Abate N, Garg A, Coleman R, Grundy SM, Peshock RM. Prediction
of total subcutaneous abdominal, intraperitoneal, and retroperitoneal
adipose tissue masses in men by a single axial magnetic resonance
imaging slice. Am J Clin Nutr 1997;65:403–8.
23. Szczepaniak LS, Babcock EE, Schick F, et al. Measurement of intra-
cellular triglyceride stores by H spectroscopy: validation in vivo. Am J
Physiol 1999;276:E977–89.
24. Drazner MH, Dries DL, Peshock RM, et al. Left ventricular hyper-
trophy is more prevalent in blacks than whites in the general pop-
ulation: the Dallas Heart Study. Hypertension 2005;46:124–9.
25. Sugisawa T, Kishimoto I, Kokubo Y, et al. Visceral fat is negatively
associated with B-type natriuretic peptide levels in patients with
advanced type 2 diabetes. Diabetes Res Clin Pract 2010;89:174–80.
26. Cheng S, Fox CS, Larson MG, et al. Relation of visceral adiposity to
circulating natriuretic peptides in ambulatory individuals. Am J Cardiol
2011;108:979–84.
27. Kotronen A, Yki-Jarvinen H. Fatty liver: a novel component of the
metabolic syndrome. Arterioscler Thromb Vasc Biol 2008;28:27–38.
28. Boorsma W, Snijder MB, Nijpels G, et al. Body composition, insulin
sensitivity, and cardiovascular disease proﬁle in healthy Europeans.
Obesity (Silver Spring) 2008;16:2696–701.
29. Okura T, Nakata Y, Yamabuki K, Tanaka K. Regional body compo-
sition changes exhibit opposing effects on coronary heart disease risk
factors. Arterioscler Thromb Vasc Biol 2004;24:923–9.
30. Magnusson M, Jujic A, Hedblad B, et al. Low plasma level of atrial
natriuretic peptide predicts development of diabetes: the prospective
Malmo Diet and Cancer study. J Clin Endocrinol Metab 2012;97:
638–45.
31. Neeland IJ, Turer AT, Ayers CR, et al. Dysfunctional adiposity and the
risk of prediabetes and type 2 diabetes in obese adults. JAMA 2012;
308:1150–9.
32. Sengenes C, Stich V, Berlan M, et al. Increased lipolysis in
adipose tissue and lipid mobilization to natriuretic peptides during
low-calorie diet in obese women. Int J Obes Relat Metab Disord 2002;
26:24–32.
33. Arner P. Differences in lipolysis between human subcutaneous and
omental adipose tissues. Ann Med 1995;27:435–8.
34. Pivovarova O, Gogebakan O, Kloting N, et al. Insulin up-regulates
natriuretic peptide clearance receptor expression in the subcutaneous
fat depot in obese subjects: a missing link between CVD risk and
obesity? J Clin Endocrinol Metab 2012;97:E731–9.
Neeland et al. JACC Vol. 62, No. 8, 2013
Natriuretic Peptides and Fat Distribution August 20, 2013:752–60
76035. Changchien EM, Ahmed S, Betti F, et al. B-type natriuretic peptide
increases after gastric bypass surgery and correlates with weight loss.
Surg Endosc 2011;25:2338–43.
36. Chen-Tournoux A, Khan AM, Baggish AL, et al. Effect of weight loss
after weight loss surgery on plasma N-terminal pro-B-type natriuretic
peptide levels. Am J Cardiol 2010;106:1450–5.
37. Iozzo P. Myocardial, perivascular, and epicardial fat. Diabetes Care
2011;34:S371–9.
38. Morabito D, Vallotton MB, Lang U. Obesity is associated with
impaired ventricular protein kinase C-MAP kinase signaling and
altered ANP mRNA expression in the heart of adult Zucker rats.
J Invest Med 2001;49:310–8.
39. Licata G, Volpe M, Scaglione R, Rubattu S. Salt-regulating hormones
in young normotensive obese subjects: effects of saline load. Hyper-
tension 1994;23:I20–4.
40. Fox CS, Massaro JM, Hoffmann U, et al. Abdominal visceral and
subcutaneous adipose tissue compartments: association with metabolic
risk factors in the Framingham Heart Study. Circulation 2007;116:
39–48.
41. Gallagher D, Kelley DE, Yim JE, et al. Adipose tissue distribution is
different in type 2 diabetes. Am J Clin Nutr 2009;89:807–14.42. Corti R, Burnett JC Jr., Rouleau JL, Ruschitzka F, Luscher TF.
Vasopeptidase inhibitors: a new therapeutic concept in cardiovascular
disease? Circulation 2001;104:1856–62.
43. Scharhag J, Herrmann M, Urhausen A, Haschke M, Herrmann W,
Kindermann W. Independent elevations of N-terminal pro-brain
natriuretic peptide and cardiac troponins in endurance athletes after
prolonged strenuous exercise. Am Heart J 2005;150:1128–34.
44. Ross R, Dagnone D, Jones PJ, et al. Reduction in obesity and related
comorbid conditions after diet-induced weight loss or exercise-induced
weight loss in men. A randomized, controlled trial. Ann Intern Med
2000;133:92–103.Key Words: body fat distribution - insulin resistance -
natriuretic peptides - visceral fat.APPENDIX
For supplementary tables, please see the online version of this article.
